Cipla Medpro SA a fully owned subsidiary of Cipla Ltd and Teva Pharmaceutical Industries Ltd. (‘Teva’) have announced that Teva’s newly acquired Allergan Generic business in South Africa (Actavis Pharma (Pty) Ltd and Pharmascript Pharmaceuticals Ltd products) will now become part of the existing Cipla-Teva supply & distribution agreement in South Africa.
Under this partnership, Cipla Medpro will market Actavis’ product portfolio, inclusive of products in the MCC pipeline. The Competition Commission approved the agreement yesterday, and it is effective as of September 27th, 2016.
The partnership leverages the commercial strength of Cipla Medpro in South Africa together with the strong global product pipeline of Teva. It spans across a number of therapeutic areas such as oncology, cardiovascular, CNS, and Over-The-Counter products. Teva’s products will benefit from Cipla Medpro’s strong relationship with healthcare professionals and pharmacies, with Cipla Medpro significantly broadening its portfolio offering.
Paul Miller, CEO of Cipla Sub-Saharan Africa, stated that “we are very pleased with the addition of these new products, including strong brands like Accurate, Lokit, Amoclan and Sudocrem. Cipla’s strategy is to grow through such alliances. Ultimately, patients benefit with better reach of quality medicines.”
Erez Israeli, President & CEO of Teva Growth Markets, noted that “the partnership with Cipla Medpro SA has enabled us to reach millions of patients in South Africa, providing them with increased access to healthcare. The addition of the Actavis portfolio is further evidence of the strength of this partnership, and we look forward to continuing to provide South Africans with high quality and affordable medicines from the world’s largest medicine cabinet.”
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products.
Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva’s net revenues in 2015 amounted to $19.7 billion. For more information, visit www.tevapharm.com.
In the interest of our patients, in accordance with SA law and our commitment to expertise, MediHub cannot subscribe to the practice of online diagnosis. Please consult a medical professional for specific medical advice. If you have any major concerns, please see your doctor for an assessment. If you have any cause for concern, your GP will be able to direct you to the appropriate specialists.